Amneal Pharmaceuticals (AMRX) Tops Q3 EPS by 3c; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts AMRX Hot Sheet
Join SI Premium – FREE
Amneal Pharmaceuticals (NASDAQ: AMRX) reported Q3 EPS of $0.26, $0.03 better than the analyst estimate of $0.23. Revenue for the quarter came in at $862.68 million versus the consensus estimate of $812.11 million.
GUIDANCE:
Amneal Pharmaceuticals sees FY2026 EPS of $1.04-$1.08, versus the consensus of $1.03. Amneal Pharmaceuticals sees FY2026 revenue of $3.15-3.25 billion, versus the consensus of $3.16 billion.
For earnings history and earnings-related data on Amneal Pharmaceuticals (AMRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ultragenyx Pharma (RARE) Misses Q3 EPS by 6c; Offers Guidance
- LATAM Airlines (LTM) Misses Q3 EPS by 135c
- First Tracks Biotherapeutics, Inc. (TRAX) Misses Q3 EPS by 88c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
